Royalty Report: Drugs, Cancer, Biotechnology – Collection: 8740


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Cancer
  • Biotechnology
  • Pharmaceuticals
  • Disease
  • Therapeutic
  • Drug Discovery
  • Genome

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 8740

License Grant
The Company entered into a research and development collaboration agreement to discover and commercialize small molecule drugs that restore control of, or otherwise intervene in, the misregulated cell cycle in tumor cells.
License Property
PD-332,991 is a highly selective inhibitor of CDK4/6, a protein that plays a key role in cancer cell cycles.  CDK4/6 has been hypothesized to have the potential to treat a variety of cancers.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 256505

License Grant
The 2018 Amendment covers adjustments in the respective roles and responsibilities of the Chinese parties, in China, for the development and commercialization of fruquintinib in the areas of future life cycle planning and development, collaborations for co-development of fruquintinib with other third-party anti-cancer agents as well as promotion and distribution rights of fruquintinib.  The 2018 Amendment now gives Licensor all planning, execution and decision making responsibilities for LCI development on fruquintinib in China.  The 2018 Amendment provides Licensor the right to promote fruquintinib in provinces that represent 30% of the sales of fruquintinib in China (“Licensor Territory”) upon the occurrence of certain commercial milestones.
License Property
Fruquintinib (brand name Elunate®) is a small molecule, selective and highly potent inhibitor of VEGFR 1, 2 and 3. VEGFR inhibitors play a pivotal role in tumor-related angiogenesis, cutting off the blood supply that a tumor needs to grow rapidly.
Fruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, fruquintinib inhibits VEGF-induced phosphorylation of VEGFRs 1, 2, and 3 which may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types.
Field of Use
Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.

IPSCIO Record ID: 27004

License Grant
Licensee and the Company have entered into a Collaborative Research Agreement dated April 1, 1986, pursuant to which, among other things, Licensee has committed to fund certain Cancer Therapeutant research projects of the Company.
License Property
Certain results and materials arising from that Collaborative Research Agreement will be useful and will be used by Licensee in its own research directed to the discovery of novel agents for the therapy of cancer.

Licensee recognizes the contribution of the Company in assisting Licensee in this process.

Royalties shall be paid for 10 years from the date of first commercial sale by Licensee of each such Cancer Therapeutant Product in each country of the world, on a country by country basis.

Update from 10K filed 2/20/1996  In April 1986, Licensee and the Company entered into a collaborative research agreement and several other related agreements. During the first five years of the collaboration, the Company and Licensee focused principally on understanding the molecular biology of oncogenes. In 1991, Licensee and the Company renewed the collaboration for a new five-year term and expanded the resources and scope of the collaboration to focus on the discovery and development of cancer therapeutic products that target oncogenes and anti-oncogenes. Oncogenes play a key role in the conversion of normal cells to a cancerous state. Anti-oncogenes, or tumor suppressor genes, encode proteins that generally function to block the proliferative growth of particular cell types. A loss of function of certain tumor suppressor genes can result in uncontrolled cell growth.

Currently, the Company's collaboration with Licensee focuses on discovering compounds that act upon eight target proteins involved in cancer. The Company's screening program has resulted in the identification of a proprietary lead compound that inhibits a protein associated with a number of major cancers. Licensee is currently conducting pre-IND safety and toxicity studies on this compound. If such studies are successful, the Company expects that Licensee may file an IND as early as the second half of 1996. The success of such studies and the continued development of this compound depends on several factors outside the control of the Company, including the amount and timing of resources devoted by Licensee and the successful optimization of the compound. There can be no assurance that this schedule will be met or that an IND for this lead compound will be filed.

All patent rights and patentable inventions derived from the research under this collaboration are owned jointly by the Company and Licensee. The Company is obligated to file, prosecute and maintain such patents. The Company has granted Licensee an exclusive, worldwide license to make, use, and sell the therapeutic products resulting from this  collaboration in exchange for royalty payments. This license terminates on the date of the last to expire of the Company's relevant patent rights.

Field of Use
The rights granted apply to the Cancer Therapeutant Product which means any product that is useful in the therapy of human cancer.

IPSCIO Record ID: 299263

License Grant
The Collaboration will seek to identify agents that modulate biological targets within the Field, including all therapeutic benefits of such agents.

Licensor grants and agrees to grant to Licensee exclusive, worldwide, except for Japan, licenses under the Licensor Patents to the extent necessary to make, have made, use and sell each compound designated as a Collaboration Lead Compound or as a Collaboration Product.

Each party hereby grants and agrees to grant to the other a non-exclusive, royalty-free license to use such partys Know-How and Patents that are conceived or reduced to practice prior to the one year anniversary of the end of the Term of the Research Collaboration.

License Property
Each Party has certain expertise in the discovery and development of agents acting in the field of cell cycle control.

The technologies relates to gene therapy and are developed in connection with performance of the Research Plan of Gene Therapy Inventions.

A Lead compound would be considered as a candidate for cGLP/cGMP studies.

Field of Use
Field shall mean research, drug discovery and development collaboration aimed at therapeutic agents to restore control of or otherwise intervene in, mis-regulated cell cycle transitions in tumor cells, vascular smooth muscle cells, or other pathological conditions.

IPSCIO Record ID: 26536

License Grant
The Licensee announced that the Licensor decided not to exercise its option under the product development and commercialization Agreement between the Licensee and the Licensor to License XL647 for further development and commercialization. The Licensee reported in May 2007 that it had notified the Licensor of it's determination that it had achieved proof-of-concept for XL647 based on data from a phase 2 clinical trial, thereby triggering a 90-day review period in which the Licensor could exercise its option. As a result of the decision by the Licensor not to exercise its option, the Licensee retains the right to develop and commercialize XL647 either independently or in collaboration with third parties.
Field of Use
The Licensee intends to move forward with the full development of XL647 in patients with non-small cell lung cancer and potentially other indications.  XL647 is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). XL647 inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. In addition, XL647 inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. In a broad array of preclinical tumor models including breast, lung, colon and prostate cancer, XL647 demonstrated potent inhibition of tumor growth and causes tumor regression. In cell culture models, XL647 retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.